Table 2 Comparisons of clinical features and laboratory findings by different thyroid dysfunction identification.

From: The relationship between thyroid dysfunction and nephrotic syndrome: a clinicopathological study

 

Normal Thyroid

Subclinical hypothyroidism

Hypothyroidism

Euthyroid sick syndrome

P

Low T3

Low T4

Low T3T4

Clinical characteristics

N

57

61

83

66

5

45

—

Age (Year)

41.3 ± 14.33

41.72 ± 15.44

38.24 ± 16.79

42.92 ± 15.9

41.4 ± 16.3

40.33 ± 16.65

0.604

Male (%)

54.4%

62.3%

49.4%

50.0%

60.0%

53.3%

0.714

Duration of NS (Month)

6.00 [1.00, 10.00]

4.00 [1.00, 7.00]

2.00 [1.00, 8.00]

3.00 [1.00, 8.00]

3.00 [2.00, 6.00]

2.00 [1.00, 7.75]

0.210

PRO (g/24 h)

4.03 ± 2.45

6.51 ± 4.33

9.71 ± 7.42*

6.71 ± 4.9

7.26 ± 5.22

10.85 ± 8.62*

<0.001

PCR (g/mmol Cr)

0.47 ± 0.4

0.79 ± 0.51

1.01 ± 0.58*

0.76 ± 0.53

0.76 ± 0.37

1.02 ± 0.8*

<0.001

ALB (g/L)

28.68 ± 6.19

24.19 ± 5.65*

19.01 ± 4.56*

25.52 ± 6.11*

22.88 ± 4.96

19.48 ± 3.99*

<0.001

SCR (umol/L)

61.50 [55.00, 75.00]

68.00 [56.00, 84.30]

69.00 [53.00, 94.70]

73.80 [52.60, 119.00]*

54.00 [53.00, 67.00]

79.90 [59.35, 138.30]*

<0.001

TG (mmol/L)

354.36 ± 87.87

366.4 ± 101.97

343.16 ± 81.35

372.28 ± 123.63

346.66 ± 97.66

373.26 ± 105.08

0.525

TC (mmol/L)

2.03 ± 1.06

2.5 ± 1.51

2.53 ± 1.8

2.14 ± 1.18

1.83 ± 0.63

2.83 ± 1.88*

0.062

LDL (mmol/L)

7.15 ± 2.24

8.14 ± 2.96

9.37 ± 3.11

7.19 ± 2.98*

6.86 ± 1.84

9.44 ± 3.66*

<0.001

FT3 (pmol/L)

4.54 ± 1.93

5.3 ± 2.5

6.27 ± 2.69*

4.44 ± 2.41

4.33 ± 1.2

6.31 ± 3.38*

<0.001

TT3 (nmol/L)

4.49 ± 0.64

4.31 ± 1

2.76 ± 0.71*

3.11 ± 1.9*

3.95 ± 0.47

2.28 ± 0.89*

<0.001

FT4 (pmol/L)

1.64 ± 0.26

1.61 ± 0.43

1.08 ± 0.27

1.14 ± 0.35

2.04 ± 0.2

0.93 ± 0.36

<0.001

TT4 (nmol/L)

15.8 ± 2.18

14.7 ± 3.02

11.05 ± 2.68*

14.61 ± 2.32*

10.74 ± 1.07*

10.34 ± 1.42*

<0.001

TSH (mU/L)

87.32 ± 12.8

84.87 ± 19.35

49.72 ± 16.71

86.53 ± 24.48

83.51 ± 1.2

48.85 ± 9.67

<0.001

RT3 (nmol/L)

2.98 [2.05, 3.60]

6.25 [5.1, 7.16]

6.98 [5.54, 9.04]

2.6 [1.50, 3.15]

3.23 [2.00, 3.27]

2.45 [1.67, 3.09]

<0.001

PRO(g/24 h)

0.36 ± 0.14

0.33 ± 0.12

0.25 ± 0.15

0.32 ± 0.11

0.28 ± 0

0.36 ± 0.16

0.214

HB (g/L)

143.14 ± 23.55

134.44 ± 26.16

135.7 ± 22.89

123.95 ± 26.87*

134.6 ± 11.44

133.8 ± 24.84

0.002

WBC (10^9/L)

7.36 ± 2.53

7.87 ± 2.92

7.47 ± 2.66

8.12 ± 3.72

6.19 ± 3

9.13 ± 4.25*

0.045

PLT (10^9/L)

202.23 ± 72.02

237.98 ± 97.93

241.43 ± 76.58*

213.26 ± 90.17

214.6 ± 29.06

241.98 ± 88.11

0.043

Coexisting diseases (%)

Hypertension

17.5%

26.2%

10.8%

27.3%

20.0%

17.8%

0.120

Diabetes

1.8%

6.6%

1.2%

10.6%

0.0%

6.7%

0.086

Pulmonary infection

7.0%

6.6%

16.9%*

15.2%*

0.0%

24.4%*

0.040

AKI

1.8%

0.0%

4.8%

4.5%

0.0%

8.9%

0.127

CKD

1.8%

4.9%

3.6%

12.1%

0.0%

13.3%

0.058

Renal biopsy (%)

MCD

28.1%

21.7%

48.8%

33.3%

20.0%

38.6%

<0.001

MPGN

3.5%

1.7%

1.2%

0.0%

0.0%

6.8%

 

MsPGN

0.0%

1.7%

2.4%

4.8%

0.0%

6.8%

 

MN

40.4%

46.7%

22.0%

23.8%

0.0%

27.3%

 

FSGS

3.5%

5.0%

1.2%

3.2%

80.0%

6.8%

 

IgAN

10.5%

10.0%

6.1%

11.1%

0.0%

4.5%

 

Secondary NS

10.9%

11.3%

14.9%

22.0%

0.0%

8.6%

 
  1. Data are expressed as mean ± standard deviation, median and interquartile range, or percent frequency, as appropriate.
  2. MN membranous nephropathy, MCD minimal-change disease, FSGS focal segmental glomerulosclerosis, MPGN membrane proliferative glomerulonephritis, MsPGN mesangial proliferative glomerulonephritis, secondary secondary reasons of nephrotic syndrome.
  3. *P < 0.05, Comparison versus normal thyroid group.
Back to article page